Influenza activity remains low in Canada, similar to
previous weeks
During week 45, influenza activity levels remained low in Canada
where most regions across the country reported no activity. The
number of regions reporting sporadic influenza activity increased
from 6 regions in week 44 to 11 regions in week 45. Localized
activity continued to be reported in the central east region of
Ontario (see map). In week 45, 3 (0.2%) of the
1,469 specimens tested were positive for influenza virus, one of
which was influenza B. Of the influenza detections to date, 86%
(19/22) were influenza A and 14% (3/22) were influenza B (see table). The ILI consultation rate increased slightly
from previous weeks (9 ILI consultations per 1,000 patient visits)
but remained below the expected range (see ILI
graph). Sentinel response rates over recent weeks have been low
(46% in week 45) but are expected to increase as the season
progresses. In week 45, no new influenza outbreaks were reported.
Since the start of the season, 3 LTCF outbreaks have been reported
(2 in Ontario and 1 in Alberta). In the current season to date, no
new laboratory-confirmed influenza-associated paediatric
hospitalizations were reported through the Immunization Monitoring
Program Active (IMPACT) network.
Antigenic Characterization:
The National Microbiology Laboratory (NML) has characterized 7
influenza viruses for the 2007-2008 influenza season: 1 A(H1N1), 4
A(H3N2) and 2 B viruses. The influenza A/H1N1 virus was
antigenically similar to A/Solomon Islands/3/2006 (which is the
influenza A(H1N1) component recommended for the 2007-2008 influenza
vaccine). Of the 4 influenza A(H3N2) viruses characterized, 3 were
antigenically similar to A/Wisconsin/67/2005 (which is the
influenza A(H3N2) component recommended for the 2007-2008 influenza
vaccine) and 1 was antigenically similar to A/Brisbane/10/2007. One
of the 3 A/Wisconsin-like viruses had reduced titer to
A/Wisconsin/67/2005 reference antiserum. The 2 influenza B isolates
characterized were antigenically similar to B/Florida/4/2006,
belonging to the B/Yamagata lineage, and is the B component
recommended for the 2008 influenza vaccine in the Southern
Hemisphere (see pie chart).
Note: The results of the strain identifications indicate that there
may be some degree of antigenic drift this season, however, the
current Canadian vaccine is still expected to provide a level of
protection against this new variant.
* The WHO recommends that the vaccines to be used in the 2007-2008 season (northern hemisphere) contain the following: an A/Solomon Islands/3/2006 (H1N1)-like virus; an A/Wisconsin/67/2005 (H3N2)-like virus; and a B/Malaysia/2506/2004-like (B/Victoria/2/1987 lineage) virus.
Antiviral Resistance:
Since the start of the season, the NML has tested 6 influenza A
isolates (all H3N2) for amantadine resistance (from Ontario,
Alberta and British Columbia). Four (67% or 4/6) of the isolates
tested were resistant to amantadine (3 of which originated from
Ontario and one from Alberta) (see
recommendation from the 2006-2007 influenza season below). Of
the 5 isolates tested for oseltamivir resistance (3 influenza A, 2
influenza B), none were found to be resistant.
CDC: A low level of influenza activity was reported in the United States during week 44 with only 2 states reporting localized activity. Of the 2,015 specimens tested for influenza virus, 50 (2.5%) were positive. Of the positive influenza detections to date, 94% (167/178) were influenza A and 6% (11/178) were influenza B. The proportion of deaths attributed to pneumonia and influenza was below the epidemic threshold, and the proportion of outpatient visits for ILI (1.2%) was below national and region-specific baseline levels. Since September 30, 2007, CDC antigenically characterized 1 influenza isolate: an influenza B virus characterized as B/Florida/04/2006 belonging to the B/Yamagata/16/1988 lineage.
EISS: In week 45, low levels of influenza activity in Europe were reported, which is typical for this time of year. There have only been sporadic laboratory confirmed cases of influenza since week 40 (N=67) of which, 66% were influenza A and 34% were influenza B. So far this season, consultation rates for ILI and/or ARI in Europe have been below the national baseline threshold. Based on antigenic and/or genetic characterization of 10 influenza viruses, 8 were A/Solomon Islands/3/2006(H1N1)-like and 2 were B/Florida/4/2006-like (B/Yamagata/16/88 lineage). However, it is too early to say which virus type or subtype will become dominant in Europe this season.
Human Avian Influenza: Since 10 November 2007, the WHO reported one new case of human infection with the H5N1 avian influenza virus from Indonesia. The case was a 31-year-old male who developed symptoms on 31 October, was hospitalized on 3 November, and died in an avian influenza referral hospital on 6 November.
Recommendation
for the Use of Amantadine for Treatment and Prevention of
Influenza
The Public Health Agency of Canada does not recommend the use of
amantadine for treatment or prevention of influenza for the
2006-2007 season. This recommendation will be revisited if new
information becomes available.
Province of reporting laboratories |
Report
Period: November 4, 2007 to November 10, 2007 |
Season to
Date: August 26, 2007 to November 10, 2007 |
||||||
Total # Influenza Tests |
# of Positive Tests | Total # Influenza Tests |
# of Positive Tests | |||||
Influenza A | Influenza B | Total | Influenza A | Influenza B | Total | |||
NL | 12 | 0 | 0 | 0 | 37 | 0 | 0 | 0 |
PE | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 |
NS | 15 | 0 | 0 | 0 | 110 | 0 | 1 | 1 |
NB | 11 | 0 | 0 | 0 | 87 | 0 | 0 | 0 |
QC | 202 | 1 | 0 | 1 | 1921 | 3 | 0 | 3 |
ON | 408 | 0 | 0 | 0 | 3184 | 5 | 1 | 6 |
MB | 29 | 0 | 0 | 0 | 386 | 0 | 0 | 0 |
SK | 115 | 0 | 0 | 0 | 848 | 0 | 0 | 0 |
AB | 612 | 1 | 1 | 2 | 4944 | 10 | 1 | 11 |
BC | 65 | 0 | 0 | 0 | 327 | 1 | 0 | 1 |
Canada | 1469 | 2 | 1 | 3 | 11864 | 19 | 3 | 22 |
Specimens from NT, YT, and NU are sent to reference laboratories in other provinces.
Note: Cumulative data includes updates to previous weeks; due to reporting delays, the sum of weekly report totals do not add up to cumulative totals.
Abbreviations: Newfoundland/Labrador (NL), Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), Saskatchewan (SK), Alberta (AB), British Columbia (BC), Yukon (YT), Northwest Territories (NT), Nunavut (NU)
Respiratory virus laboratory detections in Canada, by
geographic regions, are available weekly on the following
website:
<http://www.phac-aspc.gc.ca/bid-bmi/dsd-dsm/rvdi-divr/index-eng.php>
† sub-regions within the province or territory as defined by the provincial/territorial epidemiologist. Graph may change as late returns come in.
Influenza Activity
Level by Provincial and Territorial |
|||||||||||||
|
|||||||||||||
Note: Influenza activity levels, as represented
on this map, are assigned and reported by Provincial and
Territorial Ministries of Health, based on laboratory
confirmations, sentinel ILI rates (see graphs and tables) and
outbreaks. Please refer to detailed definitions. For areas where no data is
reported, late reports from these provinces and territories will
appear on the FluWatch website. Select single maps by
report week to get this updated information. Click on the map to view provinces/territories and maps for other weeks. |
{Strain characterization, number identified, per cent of total number}
NACI recommends that the trivalent vaccine for the 2007-2008 season in Canada contain A/Solomon Islands/3/2006 (H1N1)-like virus; an A/Wisconsin/67/2005 (H3N2)-like virus; and a B/Malaysia/2506/2004-like virus.
Note: No data available for mean rate in previous years for weeks 19 to 39 (1996-1997 through 2002-2003 seasons).
Please note that the above graphs may change as late returns come in.
To share this page just click on the social network icon of your choice.